Company / Depreciation & Amortization
Haemonetics Depreciation & Amortization History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$115.6M
FY2024
5-year range
$93.3M / $115.6M
FY2020-FY2024
Trend
+18.9%
vs FY2023
Sector context
#61 of 135
Health Care
What the data says
At $116M, Haemonetics's depreciation & amortization ranks #75 of 135 in the Health Care sector. Depreciation & Amortization has fluctuated over the past 9 years, ranging from $84M in FY2020 to $116M in FY2024.
Based on SEC 10-K filings.
$116M in FY2024 with a 5-year CAGR of +0.9%.
Increased from $93M to $116M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +0.9%
- 10-Year CAGR
- -
Sector benchmark
#75 of 135 in Health CareTop 55% of 135This company $115.6M Sector average $334.5M
▼
-65.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.9%, indicating consistent growth.
- In FY2024, depreciation & amortization increased 18.9% year-over-year.
- Ranks #61 out of 135 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $115.6M | +18.9% |
| FY2023 | $97.2M | +4.2% |
| FY2022 | $93.3M | -4.5% |
| FY2021 | $97.7M | +16.0% |
| FY2020 | $84.3M | -23.6% |
| FY2019 | $110.3M | +0.8% |
| FY2018 | $109.4M | +22.6% |
| FY2017 | $89.2M | -0.5% |
| FY2016 | $89.7M | -0.2% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026